Why the study?
The authors sought to review the current knowledge regarding the mechanisms of action and clinical indications of sulodexide.
Does Sulodexide prevent recurrent venous thromboembolism with reduced bleeding risk in patients at high risk of bleeding?
Does Sulodexide prevent recurrent venous thromboembolism with reduced bleeding risk in patients at high risk of bleeding?
Sulodexide is a therapeutic option for preventing recurrent venous thromboembolism, particularly in patients at high risk of bleeding such as the elderly.
Supports sulodexide for recurrent VTE prevention with lower bleeding risk; leaves open need for updated RCTs in broader populations.
Objectives: To review the current knowledge regarding the mechanisms of action and the clinical indications of Sulodexide, a glycosaminoglycan with established efcacy for the prevention of recurrent venous thromboembolism, with reduced bleeding risk. A critical review of the Methods: literature regarding Sulodexide in several data sources between 1975 and 2020. A total of 481 articles were found and analyzed but only 21 articles were considered for this review. Antithrombotic effects of Sulodexide include vas Results: cular endothelial protection, diminished platelet aggregation in response to several stimuli, inhibition of plasma coagulation factors Xa and thrombin, enhancement of brinolysis secondary to reducing PAI-1 and increasing of tPA, and decreased blood viscosity. Compared with other extended treatments, Sulodexide decreases mortality and bleeding episodes. Due to its broad range of pleiotropic effects and mainly a Conclusions: ntithrombotic, Sulodexide has emerged as a therapeutic option for the prevention of recurrent venous thromboembolism in subjects with high risk of bleeding, including elderly patients.
No takes yet. Share an insight, caveat, or question.
Frati-Munari et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: